Josh Riggs - May 20, 2024 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
CEO and President, Director
Signature
/s/ Josh Riggs
Stock symbol
OCX
Transactions as of
May 20, 2024
Transactions value $
$0
Form type
4
Date filed
5/22/2024, 04:56 PM
Previous filing
Apr 15, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Option to Purchase Common Stock Award $0 +90K $0.00 90K May 20, 2024 Common Stock 90K $2.76 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the options will vest and thereby be exercisable after one year of continuous service from the effective date of grant, and the balance will vest and thereby be exercisable in 36 equal monthly installments commencing one year after the date of grant, subject to continuous service through the applicable vesting date.